Parkinson’s Disease Inhalation Device Expansion

Parkinson’s Disease Inhalation Device Expansion

CRB completed the full process and facility design for a 40,000-square-foot manufacturing expansion, as well as 25,000 square feet of utility mezzanine and 5,000 square feet for plant utilities. This facility manufactures Inbrija™ (levodopa powder), an oral solid dosage spray-dried/capsule-filled product administered through a unique inhalation device.

It is the first Food and Drug Administration approved inhaled levodopa for the intermittent treatment of “off” episodes in people with Parkinson’s disease. An “off” episode is when the patient becomes stiff, slow, unable to move and has difficulty speaking. According to the Parkinson’s Foundation, more than 10 million people are living with Parkinson’s disease, and nearly 60,000 Americans are diagnosed each year.

CRB is proud to partner with Acorda Therapeutics and support its mission to develop therapies that restore function and improve the lives of people with neurological disorders.

“The client and design team CRB have been terrific to work with and as a collective team we’re excited to be a part of a project which will improve the lives of people living with Parkinson’s disease.” Darrin Ball, Project Executive at Skanska USA Building Inc.

Project Details


Catalent (formerly Acorda Therapeutics Inc.)


Chelsea, Massachusetts

Square Footage


 Return to top